CSL share price 'ticks all the defensive boxes': fundie

CSL's plasma business operates one of the largest plasma collection networks in the world.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is up 1.4% in early afternoon trade at $304.58 per share.

The global biotechnology company is outpacing the S&P/ASX 200 Index (ASX: XJO) today, with the benchmark index having only just clawed its way back into the green, up 0.1%.

That's today's price action for you.

Now, here's why this fund manager is bullish on the CSL share price moving forward.

A defensive ASX 200 share in volatile times

Speaking to Livewire, Blake Henricks, portfolio manager at Firetrail Investments said CSL fits the bill as a defensive ASX 200 share likely to remain resilient despite any future market volatility.

"It's large, it's liquid, it's healthcare. So to me, it ticks all the defensive boxes. It's in a defensive growth category," he said.

CSL's plasma business operates one of the largest plasma collection networks in the world.

Which is a core reason why Henricks sees growth ahead for the CSL share price:

I think what's really important is, the tougher the economy gets, the lower one of their key costs goes. And that's the plasma collection. This is where they pay donors to give blood and they turn that into plasma. The higher unemployment goes, the more people want to give plasma and the costs come down. On that basis, it's really attractive as a defensive. 

Henricks acknowledged that some investors may be put off by the high price-to-earnings (P/E) ratio. At the current CSL share price, that's just over 40 times.

But that P/E ratio is backwards looking. Meaning it's based on CSL's share price today and on its earnings over the past financial year.

Henricks believes those earnings are set to increase, bringing the P/E ratio sharply lower:

2023 is already written. 2024, the earnings are looking very strong in our view, and you're seeing it in a mid to high-20s P/E. They expense all their R&D. It's a very well-run business. And for a defensive, I can't go past it.

How has the CSL share price performed longer-term?

Over the past five years, the CSL share price has gained 109%, compared to a 21% gain posted by the ASX 200 over that same period.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »